#bydureon injection for diabetes

[ozempic-pens]

Why Choose Mayfair Weight Loss Clinic?

We are a dedicated weight loss clinic with the most current information and access to the newest medical procedures. Run and supported by healthcare professionals with extensive experience managing weight reduction. We have prescribers, pharmacies, and a customer support team, allowing us to give you with best support on your weight reduction journey.

Visit Byetta Insulin Pen which will help you reach your weight loss goals. Enjoy the process as you go.

[novaglobalhealthcare]

What Are My Options for Type 2 Diabetes Medications?

There are different types, or classes, of medications that work in different ways to lower blood glucose (also known as blood sugar) levels. Some options are taken by mouth and others are injected. Some of the commonly used classes of non-insulin medications include:

Metformin

Dipeptidyl peptidase 4 (DPP-4) inhibitors

Glucagon-like peptide 1 (GLP-1) and dual GLP-1/gastric inhibitory peptide (GIP) receptor agonists

Sodium-glucose cotransporter 2 (SGLT2) inhibitors

Sulfonylureas

Thiazolidinediones (TZDs)

Metformin

Metformin (Glucophage) is classified as a biguanide medication and is the only available medication in this class. Metformin lowers blood glucose levels primarily by decreasing the amount of glucose produced by the liver. Metformin also helps lower blood glucose levels by making muscle tissue more sensitive to insulin so blood glucose can be used for energy.

It is usually taken two times a day. A side effect of metformin may be diarrhea, but this is improved when the drug is taken with food.

DPP-4 Inhibitors

DPP-4 inhibitors help improve A1C (a measure of average blood glucose levels over two to three months) without causing hypoglycemia (low blood glucose). They work by preventing the breakdown of naturally occurring hormones in the body, GLP-1 and GIP. These hormones reduce blood glucose levels in the body, but they are broken down very quickly so it does not work well when injected as a drug itself.

By interfering in the process that breaks down GLP-1 and GIP, DPP-4 inhibitors allow these hormones to remain active in the body longer, lowering blood glucose levels only when they are elevated. DPP-4 inhibitors do not cause weight gain and are usually very well tolerated.

There are four DPP-4 inhibitors currently on the market in the U.S.:

Alogliptin (Nesina)

Linagliptin (Tradjenta)

Saxagliptin (Onglyza)

Sitagliptin (Januvia)

GLP-1 and Dual GLP-1/GIP Receptor Agonists

As noted in the description for DPP-4 inhibitors, GLP-1 and GIP are natural hormones in the body that help maintain glucose levels. Use of GLP-1 and dual GLP-1/GIP receptor agonists is another strategy to help use these hormones to improve blood glucose management in people with type 2 diabetes.

These medications have similar effects to the GLP-1 and GIP produced in the body but are resistant to being broken down by the DPP-4 enzyme. These medications can result in large benefits on lowering blood glucose and body weight. Some agents in this class have also been shown to prevent heart disease. Most of these medications are injected, with the exception of one that is taken by mouth once daily, called semaglutide (Rybelsus).

Injectable GLP-1 receptor agonists currently on the market include:

Dulaglutide (Trulicity)

Exenatide (Byetta)

Exenatide extended-release (Bydureon)

Liraglutide (Victoza)

Lixisenatide (Adlyxin)

Injectable semaglutide (Ozempic)

One dual GLP-1/GIP receptor agonist is currently on the market called tirzepatide (Mounjaro). How often you need to inject these medications varies from twice daily to once weekly, depending on the medication. The most common side effect with these medications is nausea and vomiting, which is more common when starting or increasing the dose.

SGLT2 Inhibitors

Glucose in the bloodstream passes through the kidneys where it can either be excreted in the urine or reabsorbed back into the blood. Sodium-glucose cotransporter 2 (SGLT2) works in the kidney to reabsorb glucose. A new class of medication, SGLT2 inhibitors, block this action, causing excess glucose to be eliminated in the urine.

By increasing the amount of glucose excreted in the urine, people can see improved blood glucose, some weight loss, and small decreases in blood pressure. Bexagliflozin (Brenzavvy), canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) are SGLT2 inhibitors that have been approved by the Food and Drug Administration (FDA) to treat type 2 diabetes. SGLT2 inhibitors are also known to help improve outcomes in people with heart disease, kidney disease, and heart failure.

For this reason, these medications are often used in people with type 2 diabetes who also have heart or kidney problems. Because they increase glucose levels in the urine, the most common side effects include genital yeast infections.

Sulfonylureas

Sulfonylureas have been in use since the 1950s and they stimulate beta cells in the pancreas to release more insulin. There are three main sulfonylurea drugs used today, glimepiride (Amaryl), glipizide (Glucotrol and Glucotrol XL), and glyburide (Micronase, Glynase, and Diabeta). These drugs are generally taken one to two times a day before meals.

All sulfonylurea drugs have similar effects on blood glucose levels, but they differ in side effects, how often they are taken, and interactions with other drugs. The most common side effects with sulfonylureas are low blood glucose and weight gain.

TZDs

Rosiglitazone (Avandia) and pioglitazone (Actos) are in a group of drugs called thiazolidinediones. These drugs help insulin work better in the muscle and fat and reduce glucose production in the liver.

A benefit of TZDs is that they lower blood glucose without having a high risk for causing low blood glucose. Both drugs in this class can increase the risk for heart failure in some individuals and can also cause fluid retention (edema) in the legs and feet.

[coppercorn-and-cauldron]

I saw your post about IIH from October. I have IIH too, diagnosed in 2020. I was considering a shunt, but decided to try exenatide as a last resort since the US govt gave it orphan drug status for IIH and clinical trials were promising. I take Bydureon injections once a week (4 months now) and it has done wonders for me - I can work full time and I'm planning on going back to school. it's expensive and I had to jump through a lot of hoops, but it's made my life liveable. my IIH is still there but I can function now.

Exenatide is usually sold as Byetta in NZ.

And I don't qualify for it under our health system unless I also have diabetes or prediabetes. I cannot afford it unfunded even if I find a Doc willing to try it as an off-label use med for IIH.

What's funny (read: infuriating) is that if I asked about it in relation to weight loss it's possible that I might be fully funded under that category.

I am trialing a CBD product currently and it seems to reduce my tinnitus, eye pain, head, neck, and upper back pain, light sensitivity, etc so it might be working to both reduce pain and pressure. And I've managed to finish 3 hardcopy books and a few ebooks in the last fortnight or so.

But I'm not anywhere near being able to study or work, yet.

Once this trial is finished it (beyetta) might be my step, treatment-wise.

[vanessapikerussell]

My new #diabetes #medication is called #bydureon to lower my #bloodsugar #bloodsugarlevels - the #bydureounpen is #huge but I’m #thankfull the needle is fairly small. I have to #inject myself once a week and my #bsl is lowering, which is great! My #health is improving. I registered as over 31 mmol or 558 mg/dl - which is WAY too high! I could have died and was rushed straight to #hospital where I learned about Bydureon and agreed to the weekly #selfinjection schedule. When I got out of hospital I spent all my food budget on healthy, low carb, low sugar foods such as salad items, vegetables, diabetic ice cream and lollies. I’ve stopped drinking #pepsimax and switched to #water with #lemonjuice or #icedtea made from #lemonsorbet #tea from #t2 @t2tea or #earlgrey #earlgreytea without milk but no #sugar I love plain #greekyoghurt with #berries such as #blackberries #raspberries and some #kiwifruit in moderation. Also bought lots of protein such as #chicken #lamb #beef #prawns and @colessupermarkets #sausages with #apple and #cider - #yummy #delicious #nom #nomnom #watchthisspace #diabetesmedicine #type2diabetes #myhealthjourney #myhealth (at An Instant On The Lips) https://www.instagram.com/p/Buy_z0lHZOO/?utm_source=ig_tumblr_share&igshid=11v2j2z2tt4lf

[bydureonpen14-blog]

The Ultimate Guide To Bydureon Pen For Diabetes

Are you someone who has had diabetes for several years and you simply can't control your sugar anymore on oral medicines? Diabetes is a progressive disease and sometimes adjustments in medicine regimens need to be made to help control blood sugar.

What Is Bydureon?

Bydureon, is a long-acting form of the medication Byetta that is given once per week. Bydureon is a GLP-1 (glucagon-like peptide 1) agonist that stimulates insulin secretion when it comes into contact with glucose.

It has also been shown to preserve beta cell function (beta cells make insulin) and has been proven to promote weight loss by delaying gastric emptying and increasing feelings of fullness. Studies have shown that people taking Bydureon lose an average of about five pounds by month six of taking the medication and have been shown to keep it off by year three. Learn more about bydureon insulin pen.

Blood Sugar Control: While clinical trials have shown that treatment with Bydureon can help to reduce A1c by about 1.5 percent, Bydureon is not used as a first-line diabetes treatment. Instead, it is typically used as a second or third agent in combination with metformin or a sulfonylurea.

Taking Bydureon?

Previously, Bydureon was only available using a syringe that was rather long and thick. Although the injection was only once per week, some people complained of discomfort. However, now Bydureon is available for use via pen. The pen is likely to be more comfortable and easier to use than the syringe.

Who Is a Candidate for Bydureon?

Discuss with your healthcare provider if you are a candidate for Bydureon. Bydureon is not meant to be used as a weight loss drug and is typically used in conjunction with other diabetes medicines. If you are someone with type 2 diabetes whose blood sugars are not at goal and can afford to lose some weight than Bydureon might be an option for you. Visit this website to get more info about ultimate guide to Bydureon pen.

Who Should Not Take Bydureon?

In animal studies, Bydureon caused rats to develop tumors of the thyroid gland. Therefore, Bydureon is contraindicated in patients with a personal or family history of medullary thyroid cancer (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). People with sensitivity to exenatide or to any product components should also not take Bydureon.

Side Effects?

Because Bydureon delays gastric emptying, the most common side effects include nausea and vomiting. Nausea commonly happens when first starting the medication and decreases over time when the body gets used the medication. Other side effects include headaches, diarrhea, redness at the injection site.

[bydureonbcisesideeffects-blog]

Everything You Should Know About The Dangers Of Bydureon

A bydureon pen is a pen pre-filled, single used pen injector, its a new treatment for type 2 diabetes and works by helping the body release its own insulin when needed to reduce glucose present in the blood.

It is a treatment of its kind as it has a unique continuous release delivery system under the skin. Each dose is made of microspheres (tiny particles) that gradually release the medicine into your body.

How To Use Bydureon Pen?

Type 2 diabetes is a serious disease as you know affecting everyone from all walks of life from children to the adults and therefore needs proper management with the use of bydureon pen which is a medication that you only take once in a week and eliminates the need for you to transfer the medication between vial and syringe.

Its indicated as an adjunct to exercise and diet to improve glycemic in adults with type 2 diabetes mellitus.

One dose lasts for seven days with each dose providing a gradual increase in the amount of exenatide in your blood as it is released from the tiny particles.

Your diabetes specialist or doctor will guide you on how to administer bydureon correctly before you use it for the first time.

Dangers Of Bydureon:

This is a prescription drug used in the treatment of type two diabetes mellitus.

It is usually injected under the skin and aids your body in the production and release of insulin when required.

It also inhibits the liver from producing excess amounts of sugar.

Like any other pharmaceutical product, it may cause a few after effects and reactions.

Possible Response To Bydureon:

Bydureon may cause thyroid tumors. A patient can develop thyroid tumors while on Bydureon.

Anaphylaxis From Some Of The Ingredients:

This is a severe allergic reaction. One may experience difficulty breathing, swelling of the throat and airway and skin rashes.

Kidney Failure:

Symptoms of kidney failure include; swelling, confusion, lethargy, weakness, shortness of breath and abnormal heart rhythms.

Stomach Problems:

Inform your physician if you notice any stomach problems such as slowed emptying, constipation, and diarrhea.

Pancreatitis:

This illness is inflammation of the pancreas. It is characterized by the following symptoms; upper abdominal pain that goes through to the back, abdominal pain that worsens after meals, fever, rapid pulse, nausea, vomiting, unintentional weight loss, abdominal tenderness and oily stool.

Injection Site Reactions:

This is damage to the skin around where the drug is usually administered. These reactions are not necessarily caused by allergens.

Hypoglycemia:

The use of by duration in addition to other similar medications greatly increases one’s chances of getting low blood sugar.

Weight Loss:

Bydureon has been seen to promote weight loss in those who are taking it.

Other common dangers of this drug are; diarrhea, headache, vomiting, loss of appetite, hair loss, constipation, and indigestion

Click here for more info about Common side effects https://bydureonguide.com/side-effects/ of bydureon pen

[rousseaubsc2b]

We went to church, then shopping and back to her flat. She hasn’t eaten much all day, a waffle for breakfast, some pretzels for a snack, then started on her laundry. I took out the rubbish and ran the dishwasher. At some point, I noticed something lying on the counter that wasn’t there earlier: an injector pen. Bydureon.

“Emma?”

“Hmm?” She was sorting clothes on the couch.

“What’s this?” I held it up.

“Oh, that’s my medicine. It’s shot day.”

“You’re diabetic?”

“Borderline.”

“What’s your A1c?” Wanting to go back to school for nursing? I knew she knew.

“Started at 5.7. I got it down to 5.5, then we switched from an appetite inhibitor to that. Six months in and I’m down another 5 points and 20 pounds total.”

“So... this is why you’re never hungry.”

“Yeah... until it’s too late.”

“I knew something was up, I just wasn’t sure what it might be.”

“Sorry,” she said. “It kind of... slips my mind. I used to be constantly hungry, so now that I’m not, it’s just not an issue. Until my sugar crashes.”

“Right.” I watched her haul a load of brightly colored clothes to the washer. “What’s your sugar when you wake up, usually?”

“Around 4.4. I start to feel weird when I get down to 4 even. All headachy and dizzy.”

“You check it often?”

“Not as often as I should. Every couple days. When I feel like something’s wrong.”

“That’s about all you need, really, that’s fine.”

“Has that warmed up yet, then?”

“What?”

“Does the glass still feel cold?”

Oh, right — is it room temperature. They’re not very nice given cold. “No, it should be fine. You, uh, need some help?”

“Actually,” her voice turned up a little. “You can help me find a spot on my belly to stab.”

...Not awkward, no. Okay. Sure.

But when she pulled up her shirt I saw she was being honest. Stretch marks, light bruises from weeks prior, a bit of a rash — scars? “You had your gallbladder out.” I looked up to her, and she nodded.

“Yeah, it was trying to starve me to death.”

“Really.” I found three of her surgery scars, then went back to looking for a decent injection site. “Right...here looks good. Hang on —“

“I’ll just come with you.” She followed me to the loo. I knew I’d seen alcohol wipes in here one night looking for ibuprofen for her, and Emma let me scrub the site on her stomach while she shook her medication to mix it. She turned the knob on the end to unlock the syringe, then took the cap off and braced herself.

Anxiety. She breathed out. “Ready, and — “ Click. She started to count under her breath. Never took her eyes off of it.

“Does it hurt?”

“No.” Ten, eleven, twelve, thirteen, fourteen, fifteen. “Not this time.” Sixteen, seventeen, eighteen, nineteen, twenty. She released it, tucked it away in a laundry detergent bottle under the sink. “The further away from the center I get the more likely it is to hurt. This isn’t so bad though. I used to do them in my leg but I started to get these big bruises and hard spots, so I had to switch.”

“Yeah, this looks better.” I wiped across her injection site with the gauze one more time before she tugged her shirt down. Just a tiny bit of bleeding, maybe a small bruise later on today.

She stole into my arms.

“Thank you,” Emma said quietly.

“Oh — Emma, no, thank you for telling me...”

“Really, I’m sorry,” she began, “like I said, it just — slips my mind, to be honest —“

“No, I get it — that’s why it’s not on your medical ID, isn’t it?”

“What?”

“Well, it’s a fairly new diagnosis, and we’re actively trying to reverse it —“

“We?” She looked up, smiled.

So did I. “Yes. We.” I smoothed her hair back, those wild afternoon curls making an appearance once again, kissed her forehead. “Now that I know what’s going on with you.”

Hiding her face in my jumper, just as snuggly as can be. God. So sweet.

“And right now, we are going to make something to eat.”

-JW

[kumarshivam]

Treatment Options for Type 2 Diabetes

Diabetes and prediabetes are two of the country's most serious health problems. Over 1.33 billion people in India are diagnosed and suffering with diabetes.

When blood sugar levels are higher than usual but not yet high enough to be diagnosed as type 2 diabetes, it is called prediabetes. Weight loss and greater activity can help you avoid being diagnosed with type 2 diabetes.

The number of Americans at risk for these disorders is even more alarming: the American Diabetes Association revealed that out of 34.2 million individuals with diabetes, 26.8 million were diagnosed and 7.3 million remained undiagnosed. The best Diabetic specialist kolkata will provide you with the best recommendations for type-2 diabetes treatment. 

Type 2 Diabetic Treatment

Type 2 diabetes has no cure, but patients may control their symptoms by eating well, staying active through regular exercise, and maintaining a healthy weight. But there are instances when this isn't enough.  Changing your lifestyle is one of the best ways to control your diabetes and not let it get out of control. 

Oral metformin, a medicine that forms the backbone of oral diabetes treatment regimens, is frequently the first drug used to treat type 2 diabetes. Different medication types may be added to metformin after that, and injectable insulin may be required for certain people.

Insulin is a hormone that allows the body to use glucose (sugar) from food to create energy.

The pancreas does not produce insulin in type 1 diabetes, thus it must be supplemented. In type 2 diabetes, the pancreas either does not produce enough insulin, or the effects of insulin are resistant, or both. The best Diabetic specialist  kolkata will provide you with the best recommendations for type-2 diabetes treatment depending on several factors. 

Medication For Diabetes Treatment

Sulfonylurea

Glipizide, glyburide, and glimepiride are examples of medications in this class. These drugs are affordable, but they can induce low blood sugar and weight gain.

Insulin Sensitizer

Pioglitazone is a medicine that is effective and does not cause hypoglycemia (low blood sugar). It can, however, result in weight gain. The best Diabetic specialist kolkata will provide you with the best recommendations for type-2 diabetes treatment. 

Agonists for the glucagon-like peptide-1 (GLP-1) receptor

Exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), and dulaglutide (Victoza, Saxenda) are examples of this drug (Trulicity). Some of these drugs are injected daily, while others are injected once a week.

Semaglutide is also available in an oral version (Rybelsus) that may be taken once a day. This sort of medicine is effective and may aid with weight loss as well as heart health. However, it is possible that it will induce adverse effects such as nausea and diarrhea.

Inhibitors of dipeptidyl peptidase-4 (DPP-4 inhibitors)

This category includes a number of drugs. Sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and vildagliptin (Vildagliptin) are all brand-name medications (Galvus).

Factors Considered By Diabetic Specialists before Recommending Treatment

Your doctor will evaluate the following considerations when deciding which treatment plan is best for you:

Heart disease, such as a history of heart attacks, strokes, or congestive heart failure, is present or absent.

Chronic kidney disease (CKD) is present or absent (CKD)

Potential side effects of diabetes treatment

Cost of medication and treatment

Individual preferences for a treatment plan

Wrapping Up!

Type 2 diabetes is a chronic and complicated disease. Managing it successfully entails employing a variety of risk-reduction methods while also attaining your blood sugar control goals. The best Diabetic specialist kolkata will provide you with the best recommendations for type-2 diabetes treatment depending on several factors. 

[jesse-pinkman123]

Injectable Drug Delivery Market To Surpass US$ 32.5 Billion By 2026 - Coherent Market Insights

Global Injectable Drug Delivery Market, by Device Type (Prefilled Syringes, Autoinjectors, Pens, Conventional Syringes, Cartridges, Ampoules, Vials, and Others), by Material Type (Glass and Plastic), by Usability (Disposable and Reusable), by Route of Administration (Intravenous, Intramuscular, and Subcutaneous), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 15,939.0 million in 2017, and is projected to exhibit a CAGR of 8.3% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Increasing product approval and launch by market players to augment the market growth

Key players in the market are focused on development of product and approval from regulatory authorities, in order to cater to the demands of patient diagnosed with chronic diseases. For instance, in October, 2018, Genentech announced the U.S. Food and Drug Administration (FDA) approval for single-dose prefilled syringes (PFS) for Xolair (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications.

Similarly, in August 2018, a new diabetes autoinjector pen by AstraZeneca- Bydureon Bcise was approved by European Commission, thereby offering additional treatment options for patients with type-2 diabetes. Moreover, the market players are focused on increasing production capacity and facility launch to expand their offerings and services, which is expected to boost the market growth. For instance, in March 2019, Gerresheimer AG announced to build a new plant at North Macedonia, Europe to produce pharmaceutical plastic systems and prefillable syringes for the pharmaceutical industry and the medical technology sector. Furthermore, increasing awareness regarding safety and concern for needlestick injuries is a major factor driving the global injectable drug delivery market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2768

According to the Health Protection Agency (HPA) report in 2012, injuries among medical and dental professionals while treating patients increased by 131% (100-231) from 2002 to 2011.

Browse 38 Market Data Tables and 32 Figures spread through 262 Pages and in-depth TOC on ‘Injectable Drug Delivery Market’- Global Forecast to 2026, by Device Type (Prefilled Syringes, Auto Injectors, Pens, Conventional Syringes, Cartridges, Ampoules, Vials, and Others), by Material Type (Glass and Plastic), by Usability (Disposable and Reusable), by Route of Administration (Intravenous, Intramuscular, and Subcutaneous), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Key players in the market are focused on adopting strategies such as collaborations and acquisitions to enhance their service offerings. For instance, in December 2016, SMC Ltd. acquired Oval Medical Technologies Ltd. to expand its drug delivery capabilities and product offerings to pharmaceutical manufacturers. Similarly, in December 2017, Numedico Technologies signed an agreement with Mana Medical Services. According to agreement, the latter will distribute ClickZip Needle Retractable Safety Syringe in New Zealand and Australia.

Key Takeaways of the Global Injectable Drug Delivery Market:

The global injectable drug delivery market is expected to exhibit a CAGR of 8.3% over the forecast period, owing to the product launch by the market players. For instance, in 2018, AbbVie GK and Eisai Co., Ltd. launched an autoinjection delivery system for HUMIRA for Subcutaneous Injection 40 mg Pen 0.4 mL and 80 mg Pen 0.8 mL.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/injectable-drug-delivery-market-2768

Among material type, the plastic segment held a dominant position in the global injectable drug delivery market in 2018, owing to launch of plastic syringes and cartridges. For instance, in June 2016, Gerresheimer launched Gx RTF ClearJect, a prefillable plastic syringe with integrated cannula, which is made from high-performance cyclo olefin polymer (COP) plastic for sensitive medications and high-viscosity agents.

Among usability, the disposable segment held dominant position in the global injectable drug delivery market in 2018, owing to significant increase in self-administration to treat chronic diseases

Among route of administration, the subcutaneous segment held a dominant position in the global injectable drug delivery market in 2018, as pens and auto-injectors are mainly used for subcutaneous delivery of biopharmaceuticals, mainly for self-administrating

Among end user type, homecare settings segment held a dominant position in the globl injectable drug delivery market in 2018, owing to cost-effective and reliable home-based care for treating chronic conditions

Key players operating in the global injectable drug delivery market include, Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, Injex Pharma GmbH

Buy-Now research report: https://www.coherentmarketinsights.com/insight/buy-now/2768

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

[pharmaphorumuk]

Novo prevents Teva’s Victoza rival launch until 2023

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

The Danish pharma said it had reached an agreement following a US patent litigation case for its daily injection Victoza (liraglutide), where Teva is licensed to launch a generic version as of 22 December 2023.

Novo said Teva could launch its generic earlier, but not before March of 2023, unless the Victoza patents are no longer in force or there is another generic on the market.

Novo could also get a further stay of execution on Victoza if it is granted an extra six months of patent life for conducting trials of the drug in children.

The FDA can grant an extra six months of patent life for drugs if the manufacturer conducts extra trials in children.

All other terms of the agreement between the two companies are confidential.

The agreement is also subject to review by the US Federal Trade Commission and the US Department of Justice.

Jesper Brandgaard, executive vice president and head of Biopharm and Legal Affairs of Novo Nordisk, said: “This settlement reflects the comprehensive US patent portfolio for liraglutide. Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative drugs against challenges.”

A daily GLP-1 inhibitor class injection, Victoza remains an important drug for Novo Nordisk and sales continue to grow despite increased competition.

Eli Lilly’s Trulicity (dulaglutide) has begun to claim market share in the GLP-1 class thanks to its more patient-friendly weekly dosing schedule.

Novo Nordisk has also launched its own weekly GLP-1 injection, Ozempic (semaglutide), which is also likely to steal sales, and AstraZeneca’s older weekly GLP-1 Bydureon (exenatide) is still a contender.

Despite all this, sales of Victoza were up by 9% in local currencies in the full year 2018 to 24,333 billion Danish kroner ($3.7 billion).

The post Novo prevents Teva’s Victoza rival launch until 2023 appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/novo-prevents-tevas-victoza-rival-launch-until-2023/

[candy--heart]

TW : intentional food restriction, non-ED related, but still. Also medication including injections.

To keep my sugar at a “normal” level, I have to starve myself. Let me clarify. I inject insulin twice a day (40 units). I also inject bydureon once a week and I take 2000 mg of metformin daily, 20 mg of glipizide daily, and 10 mg of lisinipril daily (in this case for my kidneys because of having diabetes), 1800 mg of gabapentin daily, and then I have two other pills I take for endocrine condition and two vitamins (a D and a B complex) to help because my endocrine conditions cause very low levels of both, especially D for me. 

So I do all that. I have quit soda, years ago. I drink tea with what amounts to about a half teaspoon of sugar per cup (a HUGE reduction for me). I gave up juice and the like. I use sugar free drinks like...I dunno the powder stuff you stir into water, when I want something that isn’t tea or water. Otherwise, I LIVE on water. Got a liter of it in bed with me right now.... The rest of my diet depends on money and my family already skips meals every month just to survive. So....That’s life.

Given that, I still have been fighting desperately high sugar levels lately. Nearly 400 today (making me not able to go to therapy). The only time I’ve had it anywhere near normal (111), I had starved myself for more than 24 hours. I’m a big fatty and a lot of people think, well, that’s probably good for you, but of course it isn’t. And it was painful to me physically and mentally. I go hungry from time to time just by the nature of poverty so I’m used to it in a way but...

I’m just saying the only way I am “normal” in blood sugar EVEN WITH diet changes and medication is if I starve myself to the point of physical pain like body and stomach aches as well as crippling headaches, nausea (which I’ve never understood), and the inability to sleep, and mental and emotional pain when I just can’t think straight or beat the confusion or just plain function. 

To those who want to tell me the medicine I take is bad or wrong or a crutch : I have heard it and I understand my situation better than you do.

To those who think that starving myself is probably only going to help since I’m fat or that I brought it on myself for being fat, etc etc, please click my ask button and follow the instructions there. Thank you.

[atis-luguzs]

BYDUREON® Pen, a treatment option for adults with type 2 diabetes, now available in pharmacies

BYDUREON® Pen, a treatment option for adults with type 2 diabetes, now available in pharmacies

PUBLISHED 8 September 2014

Monday, 8 September 2014

AstraZeneca(NYSE: AZN) today announced that once-weekly BYDUREON® (exenatide extended-release for injectable suspension) Pen 2 mg, a prescription medicine, is now available in pharmacies across the United States. BYDUREON is approved by the U.S. Food and Drug Administration as an adjunct to diet and exercise to improve glycemic control in…

[marketresearchinsight-blog]

Injection Pen Market Size, Share, Key Driving Factors, Segmentations, Top Insights And Forecast By 2025

The global injection pens/injectable pens/pen injectors market is expected to reach USD 67.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 9.4% CAGR during the forecast period. High demand for these devices for management of various chronic as well as acute diseases and increasing awareness in developing regions are key factors expected to drive the market.

Injectable pens have witnessed significant success in improving patient convenience during management of chronic disease, a process that might include administering intermittent injections. These devices are more convenient and affordable than other delivery systems. Ongoing studies on the same to assess their applications in management of other diseases, including but not limited to Hepatitis C and cancer, is expected to ensure swift market growth through 2025.

To request a sample copy or view summary of this report, click the link below: https://www.grandviewresearch.com/industry-analysis/injection-pens-market

Further key findings from the study suggest:

Rising incidence of diseases such as diabetes and arthritis is primarily boosting market growth

Increase in government healthcare expenditure and availability of favorable healthcare insurance policies in developed as well as developing countries is driving the market

By product, reusable injectable pens are the largest and fastest growing segment owing to the advantages associated with them such as cost effectiveness and patient convenience. Commercially available reusable injectable pens mainly include Novopen, Luxura, Berlipen, AllStar, NovoRapid, basalgar, Bydureon, Epipen and Genotropin

By dosage, variable dosage is the fastest growing segment. Some of the customizable variable pens are UnoPen, ServoPen and Ypsopen by Ypsomed, Madie by SHL Group, and Evo pen by Copernicus

North America dominates the market, followed by Europe. Technological advancements and increase in incidence of osteoporosis, arthritis, and anaphylaxis are factors that can be attributable to its largest market share

Asia Pacific is expected to be the fastest growing region over the forecast period. Better accessibility to healthcare, coupled with constantly increasing healthcare expenditure in the region, is fueling market growth

China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players. This is owing to favorable factors such as availability of labor and raw materials at significantly lower prices as compared to other regions

Key players in the market include Owen Mumford Ltd.; GlaxoSmithKline plc; Eli Lilly and Company; Mylan N.V.; AstraZeneca; Novo Nordisk; Sanofi; and Sandoz Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com For More Information: www.grandviewresearch.com

[azveille]

Les antidiabétiques analogues du GLP-1 confirment leurs bénéfices cardiovasculaires dans une vaste méta-analyse

Les analogues du GLP-1 abaissent le risque cardiovasculaire des diabétiques de type 2, confirme une vaste méta-analyse parue dans Lancet Diabetes & Endocrinology.

Soren Kristensen, de l’université de Glasgow (Royaume-Uni) et ses collègues ont réalisé une revue systématique de la littérature et la méta-analyse de 7 essais randomisés menés contre placebo, portant sur un total de 56.004 patients, afin d’obtenir une évaluation plus robuste des effets de classe des analogues du GLP-1.

Les essais inclus étaient les suivants : ELIXA (avec le lixisénatide -Lyxumia*, Sanofi-, cf dépêche du 09/06/2015 à 09:43), LEADER (avec le liraglutide -Victoza*, Novo Nordisk-, cf dépêche du 04/03/2016 à 14:06), SUSTAIN-6 (avec le sémaglutide injectable -Ozempic*, Novo Nordisk-, cf dépêche du 16/09/2016 à 08:30), EXSCEL (avec l’exénatide hebdomadaire -Bydureon*, AstraZeneca-, cf dépêche du 15/09/2017 à 16:27), Harmony Outcomes (avec l’albiglutide -Eperzan*, GlaxoSmithKline-, cf dépêche du 02/10/2018 à 12:00), REWIND (avec le dulaglutide -Trulicity*, Lilly-, cf APM FB4PSVW4), PIONEER 6 (avec le sémaglutide oral -Novo Nordisk-, cf dépêche du 23/11/2018 à 18:04).

Les analogues du GLP-1 ont, dans leur ensemble, diminué de 12% le risque d’événements cardiovasculaires majeurs, avec un suivi médian de 3,2 ans.

Les auteurs ont calculé que le nombre de patients à traiter pour éviter un événement était de 75.

Aucune hétérogénéité significative n’est apparue entre les différents sous-groupes analysés -sauf dans un sous-groupe distinguant les analogues du GLP-1 à base d’exendine-4 (lixisénatide et exénatide) de ceux plus proches du GLP-1 humain.

Cette sous-analyse suggère que les analogues à base d’exendine-4 offrent un moindre bénéfice cardiovasculaire, mais la différence n’est pas statistiquement significative. De plus, elle pourrait provenir, soulignent les auteurs, de certaines particularités des essais considérés: ELIXA incluait des patients atteints de syndrome coronarien aigu récent et EXSCEL se caractérisait par une mauvaise adhésion au traitement, avec 40% d’arrêt. L’essai AMPLITUDE-O sur l’efpéglénatide devrait éclaircir cet aspect, espèrent-ils.

Pour le reste, les résultats ne suggèrent pas qu'il y ait des bénéfices différents en prévention primaire ou secondaire, avec un suivi de plus ou de moins de 3 ans, avec un traitement hebdomadaire ou quotidien, que les patients soient âgés de plus ou moins de 65 ans, qu'ils présentent un taux initial d’hémoglobine glyquée bas ou élevé, une obésité ou non, ou un taux initial de filtration glomérulaire de plus ou de moins de 60 ml/min/m2.

Les analogues du GLP-1 ont plus spécifiquement diminué de 12% le risque de décès d’origine cardiovasculaire, de 16% celui des AVC fatals ou non et de 9% celui des infarctus fatals ou non.

Ils ont également significativement diminué la mortalité toute cause de 12% et les admissions pour insuffisance cardiaque de 9%.

Enfin, ils ont abaissé de 17% le risque d’un critère composite rénal (développement ou apparition d’une micro-albuminurie, déclin du taux de filtration glomérulaire ou hausse de la créatinine, progression d’une insuffisance rénale terminale, décès attribuable à une cause rénale), mais essentiellement du fait de la baisse du taux d’excrétion urinaire de l’albumine.

Les auteurs estiment ainsi que les analogues du GLP-1 sont "clairement cardioprotecteurs", mais avec "principalement un effet anti-athérothrombotique".

L’effet sur l’insuffisance cardiaque reste faible, en risque relatif comme absolu, et statistiquement peu robuste, soulignent-ils. Et l’effet sur le taux de filtration glomérulaire n’est pas significatif.

Eberhard Standl de l’Helmoholtz Center de Munich (Allemagne) souligne cependant dans un éditorial que, même modeste, cet effet sur l’insuffisance cardiaque contraste singulièrement avec les craintes initiales suscitées par les analogues du GLP-1.

Par comparaison, chez ces patients l’effet des inhibiteurs du SGLT2 reste plus rapide et plus prononcé. Les analogues du GLP-1 ne constitueraient donc qu’une "alternative" chez les patients présentant une insuffisance cardiaque ou une insuffisance rénale intolérants aux inhibiteurs du SGLT2 ou présentant une contre-indication, jugent les auteurs.

En revanche, chez les autres patients, ces deux traitements semblent pouvoir offrir une "synergie thérapeutique" intéressante, soulignent-ils.

Enfin, aucun risque de pancréatite, cancer du pancréas, hypoglycémie sévère ou cancer de la thyroïde n’a été mis en évidence.

[verywellhealthblr-blog]

Is it accurate to say that you are somebody who has had diabetes for quite a while and you can't control your sugar any longer on oral medications? Diabetes is a dynamic sickness and at times alterations in prescription regimens should be made to help control blood sugar.Often, individuals with diabetes can profit by utilizing an injectable drug (not insulin) notwithstanding their oral medications. Non-insulin injectable drugs, alluded to as GLP-1 agonists, (for example, Byetta and Victoza), have been appeared to help lower after-supper blood sugars and decrease weight.